LTFS
ZYNE

Ladenburg Thalmann Financial Services’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$51K Hold
8,538
– – ﹤0.01% 3524
2019
Q3 		$65K Sell
8,538
-1,895
-18% -$21.4K ﹤0.01% 3252
2019
Q2 		$143K Sell
10,433
-950
-8% -$11K ﹤0.01% 2710
2019
Q1 		$62K Buy
11,383
+4,220
+59% +$20.5K ﹤0.01% 3263
2018
Q4 		$22K Sell
7,163
-625
-8% -$3.42K ﹤0.01% 3831
2018
Q3 		$64K Sell
7,788
-977
-11% -$7.5K ﹤0.01% 3152
2018
Q2 		$76K Hold
8,765
– – ﹤0.01% 2954
2018
Q1 		$76K Sell
8,765
-59
-0.7% -$636 ﹤0.01% 2954
2017
Q4 		$110K Hold
8,824
– – ﹤0.01% 2661
2017
Q3 		$74K Buy
8,824
+7,677
+669% +$81.2K ﹤0.01% 2806
2017
Q2 		$19K Sell
1,147
-111
-9% -$2.21K ﹤0.01% 3665
2017
Q1 		$25K Buy
1,258
+1,158
+1,158% +$23K ﹤0.01% 3419
2016
Q4 		$2K Hold
100
– – ﹤0.01% 4569
2016
Q3 		$1K Hold
100
– – ﹤0.01% 4679
2016
Q2 		$1K Hold
100
– – ﹤0.01% 4640
2016
Q1 		$1K Hold
100
– – ﹤0.01% 4585
2015
Q4 		$1K Hold
100
– – ﹤0.01% 4571
2015
Q3 		$1K Buy
+100
New +$2.46K ﹤0.01% 4483

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ZYNE Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Zynerba Pharmaceuticals, Inc (ZYNE) position steady in Q4 2019 at 8,538 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #3524.

Ladenburg Thalmann Financial Services first reported a position in ZYNE in Q3 2015 and has held it in 18 quarters since. The position peaked at $143K in Q2 2019. 79 funds tracked by Wall St. Rank hold ZYNE as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 8,538 shares of Zynerba Pharmaceuticals, Inc worth $51K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its Zynerba Pharmaceuticals, Inc share count unchanged in Q4 2019.
  • Zynerba Pharmaceuticals, Inc made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3524 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and has held it in 18 quarters since.
  • Ladenburg Thalmann Financial Services's Zynerba Pharmaceuticals, Inc position peaked at $143K in Q2 2019.
  • 79 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.